02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
21:00 , Sep 28, 2017 |  BC Innovations  |  Product R&D

Wave’s purity progress

Wave Life Sciences Ltd.’s latest data releases provide the fullest view to date into how the company synthesizes its stereopure oligos and the benefits that can be derived from the chemistry. But whether the technology...
08:00 , Feb 15, 2016 |  BioCentury  |  Product Development

High fidelity

Wave Life Sciences Ltd. has set its sights on rare neuromuscular and CNS diseases where its stereopure nucleic acid technology could confer safety and efficacy advantages over competing programs. Wave was formed in 2012 from...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Kynamro mipomersen: Phase III data

The double-blind, international Phase III FOCUS FH trial in 310 patients with HeFH showed that once-weekly 200 mg subcutaneous Kynamro met the primary endpoint of reducing LDL-C from baseline to week 61 in cohort...
07:00 , Oct 16, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Mucopolysaccharidosis N-acetylglucosaminidase-a (NAGLU); insulin-like growth factor-2 (IGF-2); mannose-6-phosphate receptor (M6P receptor) Mouse studies suggest a NAGLU-IGF-2...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality. The...
07:00 , Apr 14, 2014 |  BioCentury  |  Product Development

Family resemblance

The early Phase III data appear similar for competing anti-PCSK9 mAbs from Amgen Inc. on one end and partners Regeneron Pharmaceuticals Inc. and Sanofi on the other. But starting mid-year, additional data in the populations...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Isis Pharmaceuticals, SQI Diagnostics deal

SQI will use its Ig Plex multiplexing immunogenicity technology to develop a multiplex anti-drug antibody assay for Isis. Ig Plex allows for simultaneous quantification of Ig isotype and subclass for multiple therapeutic proteins in the...
07:00 , Oct 24, 2013 |  BC Innovations  |  Cover Story

A platform for RNA

An information explosion on the number of functional RNA molecules expressed in cells and the mechanisms by which they control gene expression1,2 is driving the formation and funding of biotechs developing oligonucleotide-based therapeutics. Pharmas and...
07:00 , May 13, 2013 |  BioCentury  |  Finance

Watch me launch

Isis Pharmaceuticals Inc. (NASDAQ:ISIS) didn't wait for investors to learn launch details of hypercholesterolemia drug Kynamro mipomersen. Instead, the biotech took advantage of recent share price gains to raise $171 million in the largest follow-on...